Cancer Biomarker Global Market Report 2026

A cancer biomarker is a biological molecule found in blood, tissues, or other bodily fluids that serves as an indicator of normal or abnormal activity and the presence of a specific condition or disease, particularly cancer. These biomarkers are crucial in characterizing alterations within tumors.

The primary types of cancer biomarkers include protein biomarkers, genetic biomarkers, and those utilizing omics technologies, imaging technologies, immunoassay, bioinformatics, and cytogenetics profiling technologies. Protein biomarkers are identifiable markers in a patient's blood that correlate with significant events or signal distinct states in a biological process, such as disease progression. They are employed for accurate disease diagnosis. Cancer biomarkers find applications in various cancer types, including breast cancer, lung cancer, colorectal cancer, prostate cancer, thyroid cancer, kidney cancer, and others. These biomarkers are utilized in diagnostics, research and development, prognostics, risk assessment, and various other applications.

Tariffs are influencing the cancer biomarker market by increasing costs of imported reagents, diagnostic instruments, sequencing platforms, imaging equipment, and analytical software. Research institutes and diagnostic laboratories in North America and Europe are most affected due to reliance on imported high-value consumables, while Asia-Pacific faces higher costs for export-oriented assay production. These tariffs are raising testing costs and affecting research budgets. However, they are also encouraging domestic reagent manufacturing, regional technology development, and localized diagnostic innovation.

The cancer biomarker market research report is one of a series of new reports from The Business Research Company that provides cancer biomarker market statistics, including cancer biomarker industry global market size, regional shares, competitors with a cancer biomarker market share, detailed cancer biomarker market segments, market trends and opportunities, and any further data you may need to thrive in the cancer biomarker industry. This cancer biomarker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer biomarker market size has grown rapidly in recent years. It will grow from $25.09 billion in 2025 to $29.07 billion in 2026 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to increasing cancer prevalence worldwide, advancements in molecular biology research, expansion of oncology research funding, rising adoption of biomarker-based diagnostics, improvements in imaging and assay technologies.

The cancer biomarker market size is expected to see rapid growth in the next few years. It will grow to $52.63 billion in 2030 at a compound annual growth rate (CAGR) of 16.0%. The growth in the forecast period can be attributed to increasing demand for personalized oncology treatments, rising investments in precision medicine, expansion of biomarker-driven drug development, growing use of ai-based biomarker analysis, increasing focus on early-stage cancer screening. Major trends in the forecast period include increasing use of genetic and protein biomarkers, rising adoption of companion diagnostics, growing integration of omics technologies, expansion of liquid biopsy applications, enhanced focus on early cancer detection.

The increasing incidence of cancer is fueling the expansion of the cancer biomarker market. Cancer incidence refers to the number of newly diagnosed cases of a particular cancer type within a defined population over a specific period, typically expressed as cases per 100,000 individuals at risk. The growing burden of cancer is driving broader adoption of cancer biomarkers, as they support disease risk assessment, screening for hidden primary tumors, differentiation between benign and malignant conditions, and distinction among different malignancy types. Cancer biomarkers play a critical role in early detection, accurate diagnosis, and ongoing monitoring of cancer by signaling the presence or progression of disease, thereby enabling personalized therapies and improving patient outcomes. For example, in May 2024, a report published by the International Agency for Research on Cancer (IARC) stated that approximately 20 million new cancer cases were recorded globally in 2022, leading to 9.7 million deaths, and projections indicate that new cancer cases could exceed 35 million by 2050, reflecting a 77% increase compared to 2022. As a result, the rising incidence of cancer is expected to drive the growth of the cancer biomarker market in the coming years.

Leading companies in the cancer biomarker market are focusing on developing cutting-edge solutions, such as AI-powered cancer biomarkers, to improve diagnostic precision and tailor treatment plans for patients. AI-powered cancer biomarkers are biological indicators of cancer that are identified and analyzed using advanced artificial intelligence technologies. For example, in September 2023, Ibex Medical Analytics, a US-based company, introduced Galen Breast HER2, an AI-powered solution aimed at improving the accuracy and consistency of HER2 scoring in breast cancer patients. This innovative platform assists pathologists by automatically detecting invasive tumor regions and quantifying HER2 expression in accordance with the 2018 ASCO/CAP guidelines. The Galen Breast HER2 system uses a novel computational process to analyze immunohistochemistry (IHC)-stained slides, offering detailed visual representations of staining patterns and helping pathologists make more informed treatment decisions.

In June 2025, Illumina Inc., a United States-based genomics and sequencing technology company, acquired SomaLogic Inc. for USD 350 million, along with up to USD 75 million in performance-based milestone payments. This acquisition is intended to strengthen Illumina's multi-omics strategy by incorporating high-throughput proteomics and biomarker discovery capabilities into its sequencing ecosystem. SomaLogic Inc., a United States-based clinical diagnostics company, specializes in proteomics and has developed the SomaScan platform, a robust protein biomarker discovery solution used for advanced research and disease profiling.

Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMerieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.

North America was the largest region in the cancer biomaker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cancer biomarker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The cancer biomarker market consists of sales of epigenetic biomarkers, and metabolic biomarkers for various cancers such as melanoma, leukemia, bladder cancer, non-hodgkin's lymphoma, endometrial cancer, pancreatic cancer, and liver cancer. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Biomarker Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses cancer biomarker market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer biomarker ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer biomarker market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Biomarker Type: Protein Biomarkers; Genetic Biomarkers; Other Biomarker Types
• 2) By Profiling Technologies: Omics Technologies; Immunoassay; Bioinformatics; Cytogenetics
• 3) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Thyroid Cancer; Kidney Cancer; Other Cancers
• 4) By Application: Diagnostics; Research And Development; Prognostics; Risk Assessment; Other Applications
• Subsegments:
• 1) By Protein Biomarkers: Tumor-Specific Antigens; Circulating Tumor Protein
• 2) By Genetic Biomarkers: DNA Mutations; RNA Expression Profiles
• 3) By Other Biomarker Types: Epigenetic Biomarkers; Metabolomic Biomarkers
• Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; QIAGEN NV; Illumina Inc.; Bio-Rad Laboratories Inc.; Abbott Laboratories; bioMerieux SA; Becton Dickinson and Company; Merck & Co. Inc.; Bristol-Myers Squibb Company; PerkinElmer Inc.; Siemens AG; Exact Sciences Corporation; Novartis AG; Agilent Technologies Inc.; Hologic Inc.; Myriad Genetics Inc.; Foundation Medicine Inc.; Guardant Health Inc.; Natera Inc.; Sysmex Corporation; Biocartis Group NV; NanoString Technologies Inc.; Veracyte Inc.; Epic Sciences Inc.; Cynvenio Biosystems Inc.; Genomic Health Inc.; Oncocyte Corporation; Exosome Diagnostics Inc.; Grail Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.